CABYC Report issue

For profit Phase 2
Founded: Madrid Spain (1990)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2006
NCT00505232
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Graft vs Host Disease (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 7